Related Experiment Video
Updated: Feb 16, 2026
09:57
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
2.4K
Edelfosine: An Antitumor Drug Prototype
Sarah F Teixeira1,2, Cecilia P Rodrigues2, Cícero J S Costa2
1Department of Pharmacology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil.
Anti-Cancer Agents in Medicinal Chemistry
|January 9, 2018
Summary
Antineoplastic phospholipids, like compound ED, show potent anti-lung cancer activity. ED effectively kills cancer cells and activates immune cells, offering a promising new strategy for lung cancer treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer-related mortality.
- Drug resistance to conventional chemotherapy remains a significant challenge.
- Antineoplastic phospholipids offer a dual approach by combining cytotoxic and immunotherapeutic effects.
Purpose of the Study:
- To evaluate antineoplastic phospholipids as potential drug scaffolds for lung cancer.
- To investigate the cytotoxic and immunomodulatory properties of compound ED.
Main Methods:
- Cytotoxicity assessed via MTT, clonogenic, and 3D Matrigel assays in A549 lung cancer cells.
- Cell cycle, apoptosis, mitochondrial potential, and superoxide production analyzed by flow cytometry.
- Immunological effects on dendritic cells (DCs) and in vivo lung colonization evaluated.
Main Results:
- Compound ED demonstrated significant cytotoxicity in vitro and in vivo.
- ED induced G0/G1 cell cycle arrest and apoptosis.
- ED activated dendritic cells, increasing CD83 and decreasing PD-L1 expression.
Conclusions:
- Compound ED exhibits promising antitumor potential for lung cancer.
- ED's efficacy stems from direct cytotoxicity and immunomodulatory effects.
- Antineoplastic phospholipids represent a viable strategy for novel lung cancer drug development.
Related Concept Videos
01:24Concepts and Prototypes
574
The human nervous system handles vast amounts of information by translating sensory stimuli into neural impulses, which the brain processes, creating thoughts expressed through language or stored as memories. The brain also synthesizes information from emotions and memories, which significantly influence thoughts and behaviors. This intricate process creates a comprehensive mental picture.
The brain organizes this information using concepts, which are mental categories grouping linguistic data,...
The brain organizes this information using concepts, which are mental categories grouping linguistic data,...
574
01:30Drug toxicity: Drug–Drug Interaction
22
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
22
01:25Pharmacokinetics: Drug–Drug Interactions
477
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
477
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
167
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
167
01:26FDA Approved Drugs: Changes to Approved Drugs
279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
01:24Tissue-Drug Binding: Localization of Drugs and its Significance
475
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
475